---
title: 'Translational evaluation of metabolic risk factors impacting DBS efficacy
  for PD-Related sleep and depressive disorders: preclinical, prospective and cohort
  studies'
date: '2024-09-09'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39248306/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240909184358&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSION: In summary, this research emphasizes that DBS is a powerful
  treatment option for depression and sleep issues in PD, with its success influenced
  by metabolic risk factors. It further suggests that incorporating treatments for
  high blood sugar and cholesterol can enhance the efficacy of DBS in treating depression
  and sleep disturbances in PD, without impacting motor symptoms, highlighting the
  importance of metabolic risk management in PD patients receiving ...'
disable_comments: true
---
CONCLUSION: In summary, this research emphasizes that DBS is a powerful treatment option for depression and sleep issues in PD, with its success influenced by metabolic risk factors. It further suggests that incorporating treatments for high blood sugar and cholesterol can enhance the efficacy of DBS in treating depression and sleep disturbances in PD, without impacting motor symptoms, highlighting the importance of metabolic risk management in PD patients receiving ...